(BFRG) Bullfrog AI Holdings - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock •
BFRG: AI/ML Platform, siRNA Therapeutics, Oncology Treatments
Bullfrog AI Holdings, Inc. is a digital biopharmaceutical company leveraging artificial intelligence (AI) and machine learning (ML) to analyze medical and healthcare datasets. The companys flagship platform, bfLEAP, is designed to optimize preclinical and clinical data analysis, accelerating drug discovery and development. Bullfrog AI has established strategic licensing agreements with academic institutions, including George Washington University for siRNA targeting Beta2-spectrin to treat hepatocellular carcinoma, obesity, and liver diseases, and Johns Hopkins University for a Mebendazole formulation targeting glioblastoma and other cancers. Founded in 2017 and headquartered in Gaithersburg, Maryland, the company operates at the intersection of AI-driven analytics and precision medicine.
From a technical standpoint, BFRG has shown recent price weakness, trading below its 20-day, 50-day, and 200-day moving averages. The stocks average true range (ATR) of 0.41 indicates moderate volatility. The 20-day average volume of 1.93 million shares reflects relatively thin liquidity, which can amplify price movements. The current price of $1.80 is below the 20-day SMA of $2.73, suggesting near-term bearish momentum.
Fundamentally, Bullfrog AIs market cap of $22.83 million reflects its early-stage positioning in the AI-driven biopharma space. The price-to-book (P/B) ratio of 5.66 indicates a premium valuation relative to book value, likely driven by expectations for future growth. The price-to-sales (P/S) ratio of 530.83 is elevated, signaling investor confidence in the companys long-term revenue potential despite current losses.
3-Month Forecast: Based onAdditional Sources for BFRG Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
BFRG Stock Overview
Market Cap in USD | 23m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2023-02-13 |
BFRG Stock Ratings
Growth 5y | -54.0% |
Fundamental | - |
Dividend | 0.0% |
Rel. Strength Industry | -55.5 |
Analysts | - |
Fair Price Momentum | 1.09 USD |
Fair Price DCF | - |
BFRG Dividends
No Dividends PaidBFRG Growth Ratios
Growth Correlation 3m | -1.9% |
Growth Correlation 12m | -53.8% |
Growth Correlation 5y | -72.9% |
CAGR 5y | -48.41% |
CAGR/Max DD 5y | -0.58 |
Sharpe Ratio 12m | -1.45 |
Alpha | -69.11 |
Beta | 2.31 |
Volatility | 100.56% |
Current Volume | 259.8k |
Average Volume 20d | 542.5k |
As of March 14, 2025, the stock is trading at USD 1.59 with a total of 259,806 shares traded.
Over the past week, the price has changed by -15.87%, over one month by -59.85%, over three months by -28.38% and over the past year by -55.59%.
No, based on ValueRay Analyses, Bullfrog AI Holdings (NASDAQ:BFRG) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -54.04 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BFRG as of March 2025 is 1.09. This means that BFRG is currently overvalued and has a potential downside of -31.45%.
Bullfrog AI Holdings has no consensus analysts rating.
According to ValueRays Forecast Model, BFRG Bullfrog AI Holdings will be worth about 1.3 in March 2026. The stock is currently trading at 1.59. This means that the stock has a potential downside of -17.61%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 1.3 | -17.6% |